Eli Lilly and Company and Nektar Therapeutics have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar. NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and other chronic inflammatory conditions.
NKTR-358 is a potential first-in-class resolution therapeutic that may address an underlying immune system imbalance in patients with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, NKTR-358 may act to bring the immune system back into balance. This could lead to a profound clinical impact and healthy organ function in autoimmune conditions.
“We look forward to working with Nektar to study this novel approach to treating a number of autoimmune conditions,” said Thomas F. Bumol, Ph.D., Senior Vice President of Biotechnology and Immunology Research at Lilly. “NKTR-358 is an exciting addition to our immunology portfolio and reinforces Lilly’s commitment to sustain a flow of innovative medicines in our pipeline.”
Under the terms of the agreement, Nektar will receive an initial payment of $150 million and is eligible for up to $250 million in additional development and regulatory milestones. Lilly and Nektar will co-develop NKTR-358 with Nektar responsible for completing Phase 1 clinical development. The parties will share Phase 2 development costs 75 percent Lilly and 25 percent Nektar. Nektar will have the option to participate in Phase 3 development on an indication-by-indication basis. Nektar has the opportunity to receive double-digit royalties that increase commensurate with their Phase 3 investment and product sales. Lilly will be responsible for all costs of global commercialization. Nektar will have an option to co-promote in the U.S. under certain conditions.
“We are very pleased to enter into this collaboration with Lilly as they have strong expertise in immunology and a successful track record in bringing novel therapies to market,” said Howard W. Robin, Nektar’s President and Chief Executive Officer. “Importantly, this agreement enables the broad development of NKTR-358 in multiple autoimmune conditions in order to achieve its full potential as a first-in-class resolution therapeutic.”
Almac Discovery, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate ALM201 in the treatment of ovarian cancer.
ALM201 is a therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL. The development of ALM201 by Almac Discovery builds upon initial research work by Professor Tracy Robson who has shown that FKBPL is a naturally secreted protein with effects on a number of important tumour biology processes including cancer stem cells and angiogenesis.
Ovarian cancer ranks among the top ten diagnosed and top five deadliest cancers in most countries. Unfortunately, approximately 80% of patients present with advanced disease, therefore it is critical that clinicians are provided with as many treatment options as possible which can target this disease, either as a monotherapy or in combination with other treatments.
Dr Stephen Barr, Managing Director & President, Almac Discovery commented “The FDA’s Orphan Drug Designation of ALM201 in the treatment of ovarian cancer will allow for valuable assistance from the FDA during clinical development for either ourselves or our partners for this difficult to treat patient population.”
The FDA Office grants orphan drug designation to novel drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States.
Fareva Excelvision has just completed the validation of its new versatile ointment / gel IWK line able to handle up to 10 g tubes made of tin, aluminium or polyfoil.
Additionally 2 new 4010 Rommelag BFS (Blow Fill Seal) line has been also validated in a new workshop to increase the site capacity close to 900 millions of single dose units per year. New flow packs machines also allow to package the strips in a convenient and safe way to protect the products from water evaporation and light, ensuring product integrity even in hot climates.
In addition to those major investments, Fareva is also able to fill the preservative free bottle technology of Nemera (Novelia system), including the manipulation of cyclosporine.
Fareva is also ready for serialization up to the level 4 to support all the new regulatory expectations.
If you want to know more about Fareva, please do not hesitate to contact email@example.com
Catalent Pharma Solutions has announced the broadening of the scope of its multi-award winning OptiForm® Solution Suite platform to provide an efficient and seamless path from late-stage discovery to phase I clinical trials.
Designed to make it easier and faster for small and mid-sized innovators to develop better treatments, the new OptiForm Solution Suite service will now include more comprehensive candidate screening tools, Absorption, Distribution, Metabolism and Excretion (ADME) considerations and in silico Drug Metabolism and Pharmacokinetic (DMPK) modeling, additional bioavailability enhancing tools, materials for cGLP intravenous and oral toxicological studies, and cGMP materials for first-in-human studies.
Built on Catalent’s experience in early phase development, which has seen the company support more than 500 Investigational New Drugs (INDs), the new OptiForm Solution Suite integrates tools and services sequentially to deliver relevant data and an optimized development program to support a molecule’s progress towards the clinic.
“To ensure a program’s success, formulation selection needs to be guided by a phase-appropriate model that measures and evaluates the right data at the right time,” commented Julien Meissonnier, Catalent’s Vice President, Science & Technology. “The service provides innovators with a progressive, data-driven approach to maximize options that demonstrate in vivo efficacy and activity, acceptable safety margins in preclinical models, better downstream processing attributes, and optimal dose design for the intended patient group; supporting the selection of a development candidate with the best chances of success in the clinic and beyond.”
Gerresheimer will complete its product portfolio of prefillable syringes made of glass and plastics with an innovative, integrated, passive syringe safety solution, acquired through an exclusive licence from West Pharmaceutical Services, Inc.
“As a result of our long-standing partnership with the leading manufac-turer of packaging components and delivery devices for parenteral drugs we are pleased to have acquired the rights to market this innovative, new syringe safety solution, developed by West. By doing so, we will complement our very broad range of prefillable syringe solutions for biotech and other drugs,” said Uwe Röhrhoff, CEO of Gerresheimer AG.
Gerresheimer is a leading supplier of prefillable syringes made of glass and plastics with a broad product portfolio. The new safety solution is fully compatible with Gerresheimer’s well-established RTF (ready-to-fill) syringe portfolio. The solution is fully integrated and will be assembled on the syringe in the run of the RTF production process. It is compliant with standard nests and tubs, which enables the pharmaceutical company to use the standard filling process.
The high amount of needlestick-related injuries among healthcare workers has led to increasing demand for innovative safety solutions. International regulation has paved the way for more safety for healthcare workers and patients. The new Gerresheimer integrated safety syringe will address this market need by offering improved syringe processability and high-end user friendliness.
West will maintain its current safety solution portfolio of products, which are already commercially available. For more information, please visit www.westpharma.com
More information about Gerresheimer RTF syringes: www.gerresheimer.com/en/products/pharmaceutical-primary-packag-ing/syringes-made-of-glass
Roche and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally, mySugr is one of the leading mobile diabetes platforms in the market and will become an integral part of Roche’s new patient-centered digital health services platform in diabetes care. The acquisition allows Roche to expand its leading position in the area of diabetes management.
“We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life,” said Roland Diggelmann, CEO Roche Diagnostics. “Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes.”
“We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones,” said Frank Westermann, CEO and Co-Founder of mySugr. “The mySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, mySugr will become an indispensable companion for hassle-free life.”
As a focal point for Roche`s integrated diabetes management strategy, mySugr is foreseen to remain a separate legal entity with an open platform for all diabetes devices and services. Users will continue to have the ability to automatically upload blood glucose data from their preferred device into the mySugr logbook app as well as the facilitated data sharing with healthcare professionals and caregivers.